Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Phase 1
Completed
- Conditions
- SARS-CoV-2SARS-CoV
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05938075
- Locations
- 🇿🇦
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Botha's Hill, Kwa-Zulu Natal, South Africa
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT05870839
- Locations
- 🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States
🇺🇸University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
🇺🇸University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States
News
No news found